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Aim. To evaluate the independent role of androgen receptor (AR) gene CAG repeat polymorphism on metabolic effects of
testosterone replacement therapy (TRT) in male postsurgical hypogonadotropic hypogonadism, a condition frequently associated
with hypopituitarism and in which the TRT-related metabolic effects are combined with those deriving from concomitant
administration of metabolically active pituitary-function replacement therapies. Methods. 15 men affected by postsurgical
hypogonadotropic hypogonadism were evaluated before and after TRT. Cardiovascular risk factors (CVRFs), pituitary-dependent
hormones, and AR gene CAG repeat polymorphism were considered. Results. Testosterone, insulin-like growth factor 1 (IGF-1),
and estradiol were the only hormones, which varied significantly between the two phases. All CVRFs significantly improved after
TRT. The number of CAG triplets was positively and significantly correlated with all the variations (Δ-) of CVRFs (except for a
significant negative correlation with Δ-high-density lipoprotein); the opposite occurred between the latter and Δ-testosterone. No
correlation betweenΔ-IGF-1 or estradiol andΔ-CVRFswas found. Atmultiple linear regression, after correction forΔ-testosterone,
nearly all the associations between the number of CAG triplets and Δ-CVRFs were confirmed. Conclusions. In male postsurgical
hypogonadotropic hypogonadism, shorter AR gene CAG tract length seems to yield greater metabolic improvement after TRT,
independently of the effects of concomitant pituitary-function replacement therapies.
1. Introduction
The androgen receptor (AR) gene is located on X chromo-
some at q11-q12 and is composed of eight exons [1]. Exon 1
of the AR gene contains a polymorphic sequence of CAG
repeat, which varies in number from 10 to 35 [2] and
which encodes polyglutamine stretches of AR transactivation
domain [3]. Evidence suggests that CAG number is inversely
correlated to the transcriptional activity of AR [2]. In fact,
subjects affected by Kennedy Syndrome present a number
of CAG repeats greater than 40 together with decreased
virilization, testicular atrophy, reduced sperm production,
and infertility [4]. Similarly, other studies have shown that
shorter CAG repeats are associated with prostate cancer [5],
benign prostatic hypertrophy [6], prostate increase during
androgen treatment [7], improved seminal parameters [8, 9],
and improved mineral bone density [10].
However, great uncertainty exists in the literature regard-
ing the association between AR gene CAG repeat polymor-
phism and metabolic profile. In fact, while some authors
found a connection of the low number of CAG repeats with
low high-density lipoprotein (HDL) cholesterol levels [8, 11]
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and with increased severity of coronary heart disease [12],
others reported a relationship between the high number of
CAG repeats and worse cardiovascular risk factors (CVRFs)
[13]. These results are derived from transversal studies which
did not examine hypogonadal patients. In particular, very
little is known about the role AR gene CAG repeat poly-
morphism plays in influencing long-termmetabolic effects of
testosterone replacement therapy (TRT).
Given this premise, we decided to evaluate the inde-
pendent effect of AR gene CAG repeat polymorphism on
TRT-related metabolic changes, focusing on male postsurgi-
cal hypogonadotropic hypogonadism, a condition which is
nearly always associated with hypopituitarism and requires
the concomitant administration of metabolically active hor-
mone replacement therapies, such as recombinant growth
hormone (GH), levothyroxine, and cortisone [14–18].
2. Materials and Methods
2.1. Subjects. 15 males treated in our clinic were retro-
spectively evaluated. Inclusion criteria were, (a) hypogo-
nadotropic hypogonadism [19, 20] secondary to surgical
removal of pituitary adenoma, (b) absence of hypophy-
seal adenoma hypersecretion before surgery, (c) absence of
hypophyseal hormone deficit before surgery, (d) absence
of hypogonadism before surgery, (e) presence of clinical
follow-up data for the whole length of the study, and (f)
absence of previous diseases able to condition metabolic
parameters considered in this study (e.g., diabetes mellitus,
dyslipidaemia, arterial hypertension, etc.).
2.2. Study Protocol. The studied subjects underwent clinical
and biochemical evaluation at the beginning of TRT (time
0) and before the eighth undecanoate testosterone injection
(74–84 weeks after the first testosterone injection) (recovery
phase). 1000mg of undecanoate testosterone was adminis-
tered intramuscularly after 6 weeks before the first injection
(loading dose), followed by similar injections every 10–14
weeks, depending on blood testosterone values and clinical
symptoms [21]. All subjects presented both somatotropic
and gonadotropic function deficits [19, 20, 22]; among
them, four had also thyreotropic [23], two also corticotropic
[24], and three both thyreotropic and corticotropic function
deficits. All patients were treated with appropriate doses of
glucocorticoid (cortisone acetate, 37.5–50mg daily), soma-
totropic (recombinant human GH, 0.3–0.6mg daily), and
thyroid (levothyroxine, 75–100𝜇g daily) replacement therapy,
depending on the specific hormone deficit. Glucocorticoid
and thyroid replacement therapy began in the hours/days
immediately after surgery, depending on the presence and
degree of the specific deficit. Somatotropic replacement
therapy and TRT were started between 6 and 12 months after
surgery; no subject was givenGH replacement therapy before
TRT. Duration of hypogonadism was calculated as the time
between surgery and beginning of TRT (time 0).
This is a retrospective study and the data examined were
part of the diagnostic work-up, except for genetic data which
were collected as part of a research protocol. The study
was performed according to the Declaration of Helsinki and
approved by the institutional ethics committee. An informed
consent was obtained from each individual.
2.3. Clinical Evaluation. Among the measured clinical
parameters, weight, waist circumference, systolic (SBP), and
diastolic blood pressure (DBP) were considered in the analy-
sis.Weight, waist circumference, SBP, andDBPwere collected
according to standardmethods previously described [25, 26].
2.4. Biochemical and Hormone Evaluation. Blood samples
were taken in the morning. The following biochemical and
hormone parameters were considered: glycaemia, glycated
hemoglobin (HbA1c), total cholesterol, HDL cholesterol,
triglycerides, basal insulinemia, follicle-stimulating hormone
(FSH), luteinizing hormone (LH), total testosterone, estra-
diol, freeT3 (FT3), freeT4 (FT4), cortisol, insulin-like growth
factor-1 (IGF-1), and prolactin.
Plasma glucose was measured by photometric determi-
nation using the hexokinase method. HbA1c was measured
in whole blood using ion-exchange high performance liquid
chromatography with the Bio-Rad Variant Haemoglobin
Testing System (Bio-Rad Laboratories, Hercules, CA, USA).
Total cholesterol, HDL cholesterol, and triglycerides were
assayed enzymatically with a final Trinder reaction (ADVIA
2400 SIEMENS, Bayer Diagnostics, Tarrytown, NY, USA).
All hormone assays were carried out using immunoassay
commercial kits. As far as total testosterone is concerned, its
assay was performed using ADVIA centaur XP immunoas-
say, SIEMENS Medical Solution Diagnostics (minimum
detectable concentration: 0.1 ng/mL; intra- and interassay
coefficients of variation were, respectively, 6.2% and 4.4%
at a testosterone concentration of 0.95 ng/mL and 4.7%
and 4.7% at 3.65 ng/mL). The normal reference ranges for
the biochemical parameters studied were the following:
plasma glucose, 70–99mg/dL; HbA1c, <6.0%; total choles-
terol, <200mg/dL; HDL cholesterol, >40mg/dL for males;
triglycerides, <150mg/dL; basal insulinemia, 4–23 𝜇U/mL;
FSH, 1.7–6.9 IU/L; LH, 1.6–10.0 IU/L; total testosterone, 3–
8.5 ng/mL; estradiol, 11–47 pg/mL; FT3, 2.3–4.2 pg/mL; FT4,
0.8–1.8 ng/dL; serum cortisol (8.00 am), 7–27.5mcg/dL; IGF-
1, 66–251 ng/mL for males between 40 and 50 years; 57–
221 ng/mL for males between 50 and 60 years; 46–211 ng/mL
for males between 60 and 70 years; prolactin, 2–15 ng/mL.
Insulin sensitivity was assessed by the homeostasis model
assessment of insulin resistance (HOMA-IR) [25], which is
calculated as follows: [fasting plasma glucose (mmol/L) ×
fasting insulin (mU/L)]/22.5. Low density lipoprotein (LDL)
cholesterol was calculated according to the Friedewald et al.
[27] formula: LDL cholesterol = total cholesterol − HDL
cholesterol − triglycerides/5.0 (mg/dL).
2.5. Polymerase Chain Reaction (PCR) Amplification and
Sequencing. AR gene CAG repeats genotyping was per-
formed as previously described [28]. Briefly, genomic DNA
was isolated from peripheral leukocytes. PCR assay was
performed with 150 ng DNA; primers were used at final
concentration of 10mM.The hot-start technique was used to
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Table 1: General and hormonal characteristics of studied subjects.
General characteristics
Age (years) 55.66 ± 8.64
Duration of hypogonadism (months) 8.46 ± 1.88
Number of AR gene CAG triplets 18.13 ± 3.41
Hormonal characteristics
Time 0 Recovery phase Δ 𝑃+++
FSH (IU/L) 0.90 (0.70–1.10) 0.70 (0.50–0.90) −0.40 (−0.60–0.20) NS
LH (IU/L) 0.92 ± 0.40 0.78 ± 0.26 −0.14 ± 0.37 NS
Total testosterone (ng/mL) 1.53 ± 0.52 3.96 ± 0.36 2.42 ± 0.70 <0.001
Estradiol (pg/mL) 7.66 ± 1.95 32.80 ± 10.31 25.13 ± 11.13 <0.001
FT3 (pg/mL) 3.24 ± 0.50 3.11 ± 0.46 −0.12 ± 0.74 NS
FT4 (ng/dL) 1.24 ± 0.28 1.33 ± 0.18 0.08 ± 0.40 NS
Cortisol (mcg/dL) 14.70 (12–16.80) 13.50 (11.40–17.20) 0.80 (−5–1.5) NS
IGF-1 (ng/mL) 34.93 ± 7.59 153.13 ± 41.05 118.20 ± 43.73 <0.001
Prolactin (ng/mL) 6.82 ± 2.97 7.35 ± 3.17 0.52 ± 4.86 NS
Values are expressed as median (interquartile range) or mean ± standard deviation.
+++Statistical comparison between time 0 and recovery phase.
AR: androgen receptor;Δ: variation; FSH: follicle-stimulating hormone; LH: luteinizing hormone; FT3: free T3; FT4: free T4; IGF-1: insulin-like growth factor-1;
NS: not significant.
prevent nonspecific amplification. PCR products were puri-
fied using QIAquick PCR Purification Kit (Qiagen, Hilder,
Germany) and approximately 30 ng of the purified products
was submitted to a sequencing reaction with the BigDye
Terminator v3.1 Cycle Sequencing Kit (ABI Prism; Applied
Biosystem). The samples were sequenced on a CEQ 2000 XL
sequencer (Beckman Coulter, Fullerton, CA, USA).
2.6. Statistical Analysis. Shapiro-Wilk’s test was applied to
verify the normal distribution of the continuous variables.
Data are expressed as median (interquartile range) when
not-normally distributed and as mean ± standard deviation
when normally distributed. CVRFs and hormone variations
between the two phases (Δ-) were calculated as the value
present at the recovery phase minus the value present at time
0; statistical comparison between the two phases was made
using Student’s t-test for paired data or the Wilcoxon test
depending, respectively, on normal or nonnormal data dis-
tribution. In order to study the effect of AR gene CAG poly-
morphismonmetabolic parameters, independently from that
of the administered hormones, a two-step approach was
adopted. First, Pearson correlations of the various significant
hormonal variations and number of CAG triplets with Δ-
CVRFs were carried out. Then, multiple linear regression
analysis was performed including as dependent variables
the Δ-CVRFs, one at a time, and as independent ones the
variables which, in the Pearson correlation, were significantly
correlated with Δ-CVRFs. Significance was set at 𝑃 < 0.05.
Statistical analyses were performed using SPSS 16 package
(SPSS Inc., Chicago, IL, USA).
3. Results
Table 1 presents general and hormone parameters of the
studied subjects. Testosterone, IGF-1, and estradiol varied
significantly between the two phases, while the other hor-
mones did not change significantly (Table 1). Conversely,
all metabolic variables improved significantly after TRT
(Table 2). Table 3 shows the Pearson correlations of statisti-
cally significant hormonal variations (Δ-) between the two
phases, that is, testosterone, IGF-1, and estradiol, and of the
number of CAG triplets with the Δ-CVRFs. The number of
CAG triplets correlated positively and significantly with all
the Δ-CVRFs (except for the significant and negative corre-
lation with Δ-HDL cholesterol) (Table 3). On the contrary,
Δ-testosterone correlated negatively and significantly with all
Δ-CVRFs (except for the significant and positive correlation
with Δ-HDL cholesterol), while Δ-IGF-1 and estradiol did
not correlate significantly with any of theΔ-CVRFs (Table 3).
Multiple linear regression analysis was carried out including
as dependent variables the Δ-CVRFs and as covariates both
the number of CAG triplets and Δ-testosterone. After adjust-
ing for Δ-testosterone, CAG repeat length was still positively
and significantly associated with Δ-weight, Δ-glycemia, Δ-
HbA1c, Δ-triglycerides, Δ-HOMA-IR, Δ-SBP, Δ-DBP, and
negatively with Δ-HDL cholesterol (Table 4); positive and
almost significant (𝑃 = 0.05) association was also evident
with Δ-LDL cholesterol (Table 4).
4. Discussion
In this work we evaluated the impact of AR gene CAG
polymorphism length on metabolic effects of TRT, focusing
on male postsurgical hypogonadotropic hypogonadism, a
condition in which this aspect has not yet been studied. As
already anticipated, postsurgical hypogonadotropic hypog-
onadism is a particular type of hypogonadism in which
TRT-related metabolic changes combine with those deriving
from the frequent concomitant administration of pituitary-
function replacement hormones [14–16, 29, 30]. In fact,
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Table 2: Metabolic profile of subjects studied in the two phases.
Time 0 Recovery phase Δ 𝑃+++
Weight (kg) 79.8 ± 10.4 77.8 ± 10.9 −1.9 ± 2.0 0.002
Waist (cm) 95.7 ± 10.3 93.7 ± 9.7 −2.0 ± 1.4 <0.001
Glycaemia (mg/dL) 113.5 ± 12.0 105.6 ± 7.4 −7.8 ± 6.8 <0.001
HbA1C (%) 6.0 ± 0.1 5.9 ± 0.2 −0.1 ± 0.1 <0.001
Total cholesterol (mg/dL) 254.8 ± 39.8 236.6 ± 30.0 −18.1 ± 14.3 <0.001
HDL cholesterol (mg/dL) 39.8 ± 10.5 45.0 ± 6.1 5.2 ± 7.4 0.017
LDL cholesterol (mg/dL) 181 (138–226.6) 149 (131.4–188.4) −16.6 ((−36)–(−4)) 0.001
Triglycerides (mg/dL) 169.4 ± 29.2 159.4 ± 28.3 −10.0 ± 7.10 <0.001
HOMA-IR 9.7 ± 3.2 6.4 ± 1.8 −3.2 ± 1.9 <0.001
SBP (mmHg) 130 (120–140) 120 (110–130) −10 ((−20)–(−10)) 0.002
DBP (mmHg) 89.6 ± 7.8 83.0 ± 5.6 −6.6 ± 6.4 <0.001
Values are expressed as median (interquartile range) or mean ± standard deviation.
+++Statistical comparison between time 0 and recovery phase.
Δ: variation; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin
resistance; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 3: Pearson correlations of statistically significant hormonal variations between the two phases and number of AR gene CAG triplets
with CVRFs variations.
Δ-Testosterone Δ-Estradiol Δ-IGF-1 Number of AR gene CAG triplets
Δ-Weight r: −0.617 NS NS r: 0.755
𝑃: 0.014 𝑃: 0.001
Δ-Waist r: −0.633 NS NS r: 0.685
𝑃: 0.011 𝑃: 0.005
Δ-Glycaemia r: −0.758 NS NS r: 0.938
𝑃: 0.001 𝑃 < 0.001
Δ-HbA1c r: −0.715 NS NS r: 0.921
𝑃: 0.003 𝑃 < 0.001
Δ-Total cholesterol r: −0.750 NS NS r: 0.726
𝑃: 0.001 𝑃: 0.002
Δ-HDL cholesterol r: 0.838 NS NS r: −0.958
𝑃 < 0.001 𝑃 < 0.001
Δ-LDL cholesterol r: −0.840 NS NS r: 0.856
𝑃 < 0.001 𝑃 < 0.001
Δ-Triglycerides r: −0.757 NS NS r: 0.921
𝑃: 0.001 𝑃 < 0.001
Δ-HOMA-IR r: −0.902 NS NS r: 0.937
𝑃 < 0.001 𝑃 < 0.001
Δ-SBP r: −0.801 NS NS r: 0.935
𝑃 < 0.001 𝑃 < 0.001
Δ-DBP r: −0.828 NS NS r: 0.965
𝑃 < 0.001 𝑃 < 0.001
AR: androgen receptor; CVRFs: cardiovascular risk factors; Δ: variation; IGF-1: insulin-like growth factor-1; HbA1C: glycated hemoglobin; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; SBP: systolic blood pressure; DBP: diastolic blood
pressure; NS: not significant.
administration of replacement cortisol therapy in subjects
affected by adrenocortical failure increases and normalizes
glycaemia and blood pressure and favours weight recovery
[14]. GH replacement therapy, instead, produces an improve-
ment of the lipid profile and increases waist circumference,
body mass index (BMI), and glycaemia in patients with GH
deficiency [15]. Similarly, levothyroxine administration in
hypothyroid patients induces a decrease in total and LDL
cholesterol [16]. Moreover, TRT in hypogonadal males is
able to influence metabolic parameters causing a reduction
of fasting plasma glucose, HOMA-IR, triglycerides, waist
circumference, and usually augmenting HDL cholesterol
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Table 4: Influence of AR gene CAG repeat length on metabolic
parameters.
AR gene CAG repeat length
Unstandardized 𝛽 coefficient
(95%CI)+++ 𝑃
Δ-Weight (kg) 0.454 (0.023–0.885) 0.041
Δ-Waist (cm) 0.218 ((−0.125)–(0.561)) NS
Δ-Glycaemia (mg/dL) 1.970 (1.195–2.745) <0.001
Δ-HbA1c (%) 0.038 (0.022–0.053) <0.001
Δ-Total cholesterol (mg/dL) 1.414 ((−1.562)–(4.390)) NS
Δ-HDL cholesterol (mg/dL) −1.817 ((−2.487)–(−1.147)) <0.001
Δ-LDL cholesterol (mg/dL) 2.845 ((−0.005)–(5.696)) 0.050
Δ-Triglycerides (mg/dL) 1.927 (1.023–2.832) <0.001
Δ-HOMA-IR 0.349 (0.177–0.520) <0.001
Δ-SBP (mmHg) 2.453 (1.333–3.574) <0.001
Δ-DBP (mmHg) 1.671 (1.134–2.209) <0.001
+++: adjusted for Δ-testosterone; AR: androgen receptor; CI: confidence
interval; Δ: variation; HbA1c: glycated hemoglobin; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostasis model
assessment of insulin resistance; SBP: systolic blood pressure; DBP: diastolic
blood pressure; NS: not significant.
[19, 31–34]; also, estrogens, which increase after TRT due to
aromatase-mediated conversion [35, 36], have been found to
be positively associated with metabolic syndrome [37].
In our subjects we found that shorter length of AR
gene CAG repeat polymorphism favours the improvement
of many of the CVRFs after TRT independently from
the metabolic effects of the pituitary-function replacement
therapies. Our findings agree with a large study carried
out on 1859 men aged 20–79 years showing that subject
with CAG repeat length lower than 22 had lower levels of
BMI, glycaemia, SBP, and percentage of hypertension [13].
Moreover, our data confirm the tendency, already highlighted
in the only other study on the same topic, which included
66 men affected by hypogonadism of various aetiologies (i.e.,
primary, secondary, and late onset hypogonadism), reporting
that the SBP and DBP decrease following TRT occurred
mainly in subjects with shorter CAG repeat length [38]. It
is also worth mentioning that, in their study, no influence
of AR gene CAG repeat polymorphism on lipid profile
improvement was evident [38]; probably the heterogeneity
of the sample examined by those authors and the different
statistical methods used could explain this discrepancy.
Nevertheless, we cannot avoid mentioning those studies
which found a completely different association between AR
gene CAG polymorphism and metabolic profile. In fact,
Skjærpe et al. studying 172 men, aged 60–80 years, found
that those with a CAG length below 21 had higher values
of glycaemia, c-peptide, and HbA1c, as compared to those
with CAG length over 21 [39]. In line with these findings,
in 131 men undergoing coronary angiography, it has been
reported that those with short AR had significant coronary
artery disease more frequently than men with long AR
[12]. Moreover, in 110 healthy men the number of AR gene
CAG repeats was found to be positively correlated with
HDL cholesterol levels and flow-mediated vasodilatation, a
measure of endothelial function [40].
Interestingly, in our sample TRT led to an increase in
HDL cholesterol. This finding is in agreement with a recent
meta-analysis [41] and with the previously mentioned work
by Zitzmann and Nieschlag [38] who reported a significant
increase in HDL cholesterol from 42.4 ± 11.3mg/dL to 50.1
± 8.9mg/dL (resp., mean and standard deviation). However,
at variance with this, some evidence shows that TRT may
also have the opposite effect on HDL cholesterol levels in
hypogonadal men [42, 43]. Although a variety of factors,
like duration of study, fat distribution, obesity, diet, age,
alcohol intake, exercise, and smoking [38, 43], have been
considered to explain these diverse results, in our opinion
more attention should be given specifically to the length of
CAG polymorphism which could represent the dominating
factor able to condition the variations of HDL cholesterol
following TRT.
5. Conclusions
In conclusion, our study suggests that, in men affected by
postsurgical hypogonadotropic hypogonadism, the shorter
length of AR gene CAG tract is associated with an improved
metabolic effect of TRT, independently of the effects of other
concomitant pituitary-function replacement therapies. If our
data will be confirmed by further studies, genetic analysis
of AR gene CAG repeat polymorphism could be introduced
in clinical practice as an adjunctive factor in evaluating
cardiovascular risk in hypogonadal men undergoing TRT.
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